Thanks NZT,
Something often overlooked in my view is that 43% of patients discontinued taking Relvrio due to the side effects you have pointed out. So that $UD381 million could easily have been $US500 million in it's first 7 months and was growing exponentially. So it's sale could have been significantly more than US1 billion in its first year. Add to that 5000 new cases each year.
Gets interesting doesn't it.
Morgans by their pwn admission were conservative in their estimations [As they should be] and said they may have to come back and review them.
Cheers
Thanks NZT, Something often overlooked in my view is that 43% of...
Add PAA (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
22.5¢ |
Change
0.010(4.65%) |
Mkt cap ! $109.4M | |||
| Open | High | Low | Value | Volume |
| 21.5¢ | 22.5¢ | 21.5¢ | $300.8K | 1.361M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 168231 | 22.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 23.0¢ | 128833 | 4 |
View Market Depth
| Last trade - 10.38am 14/10/2024 (20 minute delay) ? |
| PAA (ASX) Chart |